Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind study of ZD4054 in hormone-resistant prostate cancer with bone metastases
2007-003227-20Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing ZD4054 10 mg with Placebo (2 arms). Primary endpoint: Overall survival. Started Jul 2007; status: terminated.
02
Drugs
zibotentan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2007-003227-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003227-20.